Press release content from Business Wire. The AP news staff was not involved in its creation.
Global Thyroid Function Test Market Growth, Trends, and Forecasts Report 2020-2025 - ResearchAndMarkets.com
February 12, 2021 GMT
DUBLIN (BUSINESS WIRE) Feb 12, 2021
The thyroid function test market is expected to witness a CAGR of 6% during the forecast period. Certain factors that are driving the growth of the market include rising incidence of thyroid disorders, increasing consumption of tobacco and alcohol, and sedentary lifestyle.
ADVERTISEMENT
Thyroid diseases have become a significant public health concern across the world. The risk factors include genetic background, environmental exposures, insufficient iodine intake, exposure to polychlorinated biphenyls, radiation from nuclear fallout and medical radiation, and alcohol and tobacco consumption.
Share this article
CARLSBAD, Calif., Dec. 18, 2020 /PRNewswire/
Qualigen Therapeutics, Inc. (Nasdaq: QLGN) today announced the closing of its previously announced registered direct offering with a single institutional investor for the purchase and sale for $12,000,000 of (i) 2,370,786 shares of common stock, (ii) 1,000,000 pre-funded common stock Warrants (i.e., warrants to purchase shares of Qualigen common stock, for which the exercise price is almost entirely prepaid), (iii) 1,348,314 two-year common stock Warrants with an exercise price of $4.07 per share, and (iv) 842,696 common stock Warrants (first exercisable 6 months after issuance, and with an expiration date 30 months after issuance) with an exercise price of $4.07 per share.
Press release content from PR Newswire. The AP news staff was not involved in its creation.
Qualigen Therapeutics Announces Issuance of U.S. Patent for Expanded Applications of ALAN Anticancer Platform Technology
December 15, 2020 GMT
CARLSBAD, Calif., Dec. 15, 2020 /PRNewswire/ Qualigen Therapeutics, Inc. (Nasdaq: QLGN), a biotechnology company focused on developing novel therapeutics for the treatment of cancer and infectious diseases, today announced that the United States Patent and Trademark Office has issued a patent entitled “Anti-Nucleolin Agent-Conjugated Nanoparticles as Radio-Sensitizers and/or MRI Contrast Agents” regarding the Company’s ALAN (Aptamer-Linked Anti-Nucleolin) technology. This patent issued to the University of Louisville (UofL) protects the ALAN technology for use with cancer radiation therapy and for imaging tumors utilizing magnetic resonance imaging (MRI). The novel ALAN technology has several other potential applications, including its use as
Share this article
Share this article
CARLSBAD, Calif., Dec. 16, 2020 /PRNewswire/ Qualigen Therapeutics, Inc. (NASDAQ: QLGN) ( Qualigen or the Company ), today announced it has entered into a definitive agreement with a single institutional investor for the purchase and sale for $12,000,000 of (i) 2,370,786 Common Shares, (ii) 1,000,000 Pre-Funded Warrants (iii) 1,348,314 Common Warrants exercisable immediately and (iv) 842,696 Common Warrants exercisable six (6) months after issuance at a combined purchase price of $3.56 in a registered direct offering. The Common Warrants will have an exercise price of $4.07 per share and have a term of two years. The closing of the offering is expected to occur on or about December 18, 2020, subject to the satisfaction of customary closing conditions.